HOME >> BIOLOGY >> NEWS
Tigecycline - Candidate antibiotic produces 74 percent cure rate in cSSSI patients

Results in Treatment of Hospital Patients with Complicated Skin Infections Reported in Clinical Therapeutics

Oklahoma City, OK An antibiotic, currently being tested in clinical trials, produced a 74 percent cure rate for hospitalized patients with possibly life-threatening, complicated skin and skin structure infections (cSSSI). Tigecycline, a candidate antibiotic drug, produced these promising results in a study led by Russell G. Postier, M.D., OU Physicians Chairman of Surgery and John A. Schilling Professor of Surgery at the University of Oklahoma College of Medicine.

"Tigecycline displayed promising efficacy against a wide spectrum bacteria commonly related to complicated skin infections, with an acceptable safety profile. These data warrant further investigation in blinded comparator clinical trials, said Postier, John A. Schilling Professor and chairman of surgery, OU Physicians and the study's principle investigator. Results of the multicenter, phase 2 will be published in the May 2004, issue of Clinical Therapeutics.

In the study, 85 percent of patients who received 50-milligram (mg) doses of tigecycline were cured at the end of their seven- to 14-day treatment, and 74 percent were cured at the test-of-cure visit (the study's primary outcome measure), about 21 days after their initial dose of tigecycline. Similarly, 78 percent of patients on the 25-mg doses were cured at the end of treatment, and 67 percent at the test-of-cure visit. The decline in rates directly resulted from patients receiving either additional antibiotics or surgery between the end of their treatments and their test-of-cure visits.

The 50 mg group also had a higher overall bacterial eradication rate at the end of therapy, 74 percent, than the 62 percent rate of the 25 mg group. At the test-of-cure visit, the rates were 70 and 56, respectively. Additionally, the trial used laboratory tests to document tigecycline activity against
'"/>

Contact: Jennifer Petra
jpetra@porternovelli.com
212-601-8110
Porter Novelli
23-May-2004


Page: 1 2 3

Related biology news :

1. Tigecycline - antibiotic evaluated in surveillance trial
2. AAAS US Presidential Candidates Forum
3. US Presidential Candidates Forum
4. Candidate genes found which may play a role in cancer progressing from non-invasive to invasive
5. UCSD And NIH Researchers Isolate Candidates For Genetic Basis Of Human Taste
6. New Tuberculosis Vaccine Candidate Developed: Improved Delivery Of Antigens By Current Vaccine BCG (Bacille Calmette-Gurin)
7. Candidate Regulator Of The Temporal Component Of Neurotransmitter Release Identified
8. Duke Researchers Discover Candidate Susceptibility Gene For Autoimmune Disease
9. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
10. Smart antibiotics may result from UCLA research
11. K-State researcher working to improve alternatives to equine antibiotics

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... August 25, 2020 , ... ... targeting mitochondria, in partnership with Essex Bio-Technology, a bio-pharmaceutical company specializing in ... 3 VISTA-2 study of SkQ1 ophthalmic solution in patients with moderate to ...
(Date:8/23/2020)... , ... August 21, 2020 , ... ... Corporation has been published and is now available on the company’s global ... diffraction—serves the X-ray analysis community, presenting current news and crystallographic research. , ...
(Date:8/21/2020)... ... August 19, 2020 , ... ... conference and expo uniting life science, data science, informatics and IT leaders goes ... “In this period of uncertainty and change, Bio-IT takes the leadership role of ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 30, 2020 , ... ... for the life sciences industry, today announced the release of its signature ... for Medical Science Liaisons (MSLs) and other field medical professionals. , ...
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra , a ... and food industries, is pleased to announce that Charles Galea has joined its ... , Charles is an accomplished and results-driven sales executive with over 10 years ...
(Date:7/7/2020)... SAN DIEGO (PRWEB) , ... July 06, 2020 , ... ... a new program featuring up to 200 million stem cells. Depending on the patient's ... of seniors in the US will die having some form of Alzheimers dementia, and ...
(Date:6/28/2020)... ... June 25, 2020 , ... The Indoor Lab, a leading provider of ... businesses of all types to ensure cleanliness, distancing and occupancy with its patent pending ... Space™ enabled business will provide a health performance index system that scores all aspects ...
Breaking Biology Technology:
Cached News: